Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2001

View Archived Issues

New therapeutic areas unfold for galantamine

NeoPharm seeks orphan drug status for IL-13-PE38

Atrix licenses novel growth-promoting peptide from Tulane

Pump therapy with insulin aspart approved by EMEA

Antifibrotic compounds the focus of a FibroGen/Sankyo collaboration

Nonfeminizing estrogen targeting neurodegenerative diseases completes phase I

Novel chelator designed by D-Pharm commences phase II clinical development for stroke

DB-289 enters phase II trials in Africa for trypanosomiasis

Oralin is a suitable substitute for injected insulin according to EASD presentations

Intercalating agent may be useful in MS; preclinical data presented at ECTRIMS 2001

Increase in ACh efflux may underlie cognition-improving effects of atypical antipsychotics

FDA requires further information for approval of Plenaxis

Evidence presented in Nice supports lavender aromatherapy in dementia-associated agitation

Novartis launches NAVIGATOR trial for diabetes and cardiovascular disease prevention

Stimulation of exocytosis from pancreatic beta-cells by imidazolines is PLA2-dependent

Cell Pathways completes phase I study of Aptosyn/Taxotere combination regimen, phase II begins

New glucose transport stimulator under study at Korean centers

Epimmune updates HIV vaccine program

First clinical data on peptide for autoimmune diabetes presented during EASD meeting

Promising preclinical results reported for Cel-Sci's HIV immunotherapeutic

Phase I rhASB trial successfully meets its primary objective

Rituximab now available in Japan

Urotensin-II receptor antagonists discovered by GSK team

Boehringer Ingelheim reports new piperazine MTP inhibitors

Antithrombotic benzimidazoles in early research at Boehringer Ingelheim

Joint research at Karo Bio and Abbott leads to liver-selective GR antagonists

Subtype-selective nAChR ligands designed at British university

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...